Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially ...
Arbutus Biopharma Corporation ABUS announced updates on its hepatitis B virus (“HBV”) pipeline candidates. The company’s most advanced pipeline candidate, ARB-1467, is an RNAi agent targeting HBV ...
Following a decision from the U.S Patent & Trademark Office, shares of Arbutus Biopharma Corp (Nasdaq: ABUS) stock soar over 90%. But with the broader market selling off, what’s next for the biopharma ...
The company's cash runway has been extended into the first quarter of 2026. ABUS is reducing its workforce by 24% as a result of recent pipeline optimization. Multiple data presentations are upcoming ...
Arbutus Biopharma CorporationABUS announced updates on its hepatitis B virus ("HBV") pipeline candidates. The company's most advanced pipeline candidate, ARB-1467, is an RNAi agent targeting HBV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback